Compare WTRG & RDY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WTRG | RDY |
|---|---|---|
| Founded | 1901 | 1984 |
| Country | United States | India |
| Employees | 1615 | N/A |
| Industry | Water Supply | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.6B | 11.6B |
| IPO Year | 1994 | 2001 |
| Metric | WTRG | RDY |
|---|---|---|
| Price | $37.68 | $13.67 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | ★ $43.50 | $16.90 |
| AVG Volume (30 Days) | 1.8M | ★ 2.5M |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | ★ 3.47% | 0.52% |
| EPS Growth | ★ 1.38 | N/A |
| EPS | ★ 2.20 | N/A |
| Revenue | ★ $2,474,615,000.00 | N/A |
| Revenue This Year | $5.07 | $7.72 |
| Revenue Next Year | $7.31 | $3.50 |
| P/E Ratio | ★ $17.98 | $18.67 |
| Revenue Growth | ★ 18.62 | N/A |
| 52 Week Low | $36.32 | $12.77 |
| 52 Week High | $42.37 | $16.17 |
| Indicator | WTRG | RDY |
|---|---|---|
| Relative Strength Index (RSI) | 36.66 | 52.74 |
| Support Level | $37.29 | $12.90 |
| Resistance Level | $40.01 | $13.96 |
| Average True Range (ATR) | 1.02 | 0.26 |
| MACD | -0.13 | 0.11 |
| Stochastic Oscillator | 0.97 | 62.94 |
Essential Utilities is a Pennsylvania-based holding company for US water, wastewater, and natural gas distribution utilities. The company's water business serves 3 million people in eight states. Its largest service territory is in Pennsylvania, primarily suburban Philadelphia. Its Peoples subsidiary serves more than 740,000 gas distribution customers in Pennsylvania and Kentucky. It completed the sale of its West Virginia gas utility and the bulk of its nonregulated assets in 2024. Essential shareholders would own a 31% stake in American Water Works if the proposed all-stock merger closes in 2027.
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (about 20% of its generics sales), Russia (10%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.